Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 147

Sort by

Sort Order Select

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia

Yu Liu, Wenbing Liu, Yihan Mei, Qing Rao, Runxia Gu, Min Wang, Jianxiang Wang, Shaowei Qiu

Blood (2024) 144 (Supplement 1): 328.

https://doi.org/10.1182/blood-2024-194287

Published: 2024

Journal Articles

Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China

Shiyuan Wang, Xiaoming Liu, Yongjun Fang, Kailin Xu, Hongsheng Zhou, Fei Li, Xianmin Guan, Yingyi He, Yi Feng, Lulu Lyu, Qunhui Peng, Xiaofan Zhu, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 7200.

https://doi.org/10.1182/blood-2024-201125

Published: 2024

Journal Articles

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Blood (2024) 144 (Supplement 1): 848.

https://doi.org/10.1182/blood-2024-203303

Published: 2024

Journal Articles

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

Yuting Yan, Yin Liu, Fan Yang, Jiamei Liu, Yanfei Chen, Ying Yu, Xiong Wenjie, Tingyu Wang, Zhijian Xiao, Jianxiang Wang, Thomas J. Kipps, Robert Peter Gale, Lu-Gui Qiu, Jifang Zhou, Shuhua Yi

Blood (2024) 144 (Supplement 1): 7820.

https://doi.org/10.1182/blood-2024-204512

Published: 2024

Journal Articles

The Genetic Landscape of DDX41 Gene Variants in Myeloid Neoplasms: A Large Single-Center Cohort Study from China

Li Qin, Yujiao Jia, Haoxu Wang, Xiaoxue Han, Shiqiang Qu, Huijun Wang, Qi Sun, Chengwen Li, Jigang Xiao, Hui Wei, Yingchang Mi, Jianxiang Wang, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 5717.

https://doi.org/10.1182/blood-2024-199897

Published: 2024

Journal Articles

Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-Risk AML

Shulian Chen, Xiaoyu Zhang, Yi He, Sizhou Feng, Mingzhe Han, Xingli Zhao, Jie Bai, Lijuan Li, Zhihua Zhang, Wang Ying, Jianxiang Wang, Weihua Zhai, Erlie Jiang

Blood (2024) 144 (Supplement 1): 6054.

https://doi.org/10.1182/blood-2024-202404

Published: 2024

Journal Articles

Multiomics Characterization and Comprehensive Omics-Based Classification System in Adult Patients with B-Cell Acute Lymphoblastic Leukemia

Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi

Blood (2024) 144 (Supplement 1): 5908.

https://doi.org/10.1182/blood-2024-198988

Published: 2024

Journal Articles

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Blood (2024) 144 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2024-202324

Published: 2024

Journal Articles

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Blood (2024) 144 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2024-200713

Published: 2024

Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Blood (2024) 144 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2024-199983

Published: 2024

Journal Articles

ADGRG1/GPR56 As a Marker of CD8 + Tumor-Reactive T Cells in Acute Myeloid Leukemia

Yihan Mei, Yu Liu, Wenbing Liu, Manling Chen, Qing Rao, Min Wang, Shaowei Qiu, Runxia Gu, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2024-194281

Published: 2024

Journal Articles

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1504.3.

https://doi.org/10.1182/blood-2024-205101

Published: 2024

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia

Wenbing Liu, Yu Liu, Anli Lai, Runxia Gu, Ying Wang, Qing Rao, Yingchang Mi, Hui Wei, Shaowei Qiu, Min Wang, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2024-198599

Published: 2024

Journal Articles

Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, Pau Montesinos, Pankit Vachhani, Cristina Papayannidis, Jessica T. Leonard, Maria R. Baer, Josep-Maria Ribera, James McCloskey, JianXiang Wang, Sujun Gao, Deepali Rane, Shien Guo

Blood (2024) 144 (Supplement 1): 2825.

https://doi.org/10.1182/blood-2024-208755

Published: 2024

Journal Articles

Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation

Bingqing Huang, Yujiao Jia, Haoxu Wang, Huijun Wang, Qi Sun, Chengwen Li, Hui Wei, Yingchang Mi, Xiaofan Zhu, Jianxiang Wang, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2024-194421

Published: 2024

Journal Articles

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Mark J. Levis, Harry Erba, Pau Montesinos, Elzbieta Patkowska, Jorge E. Cortes, Herve Dombret, Alexander E. Perl, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Li Liu, Yasser M. Mostafa Kamel, Karima Imadalou, Abderrahmane Laadem, Mikkael A. Sekeres, Kristy Burns

Blood (2024) 144 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2024-207305

Published: 2024

Journal Articles

Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Alexander E. Perl, Mark J. Levis, Andrew Wei, Hee-je Kim, June-won Cheong, Yu Zhang, Jian Li, Hisayuki Yokoyama, Naoko Hosono, Nahla Hasabou, Dina Elsouda, Jamie Jung-Hee An, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2024-204831

Published: 2024

Journal Articles

CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia

Chengcai Guo, Yu Liu, Qing Rao, Runxia Gu, Shaowei Qiu, Min Wang, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2734.

https://doi.org/10.1182/blood-2024-194291

Published: 2024

NARROW

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia

Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

The Genetic Landscape of DDX41 Gene Variants in Myeloid Neoplasms: A Large Single-Center Cohort Study from China

Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-Risk AML

Multiomics Characterization and Comprehensive Omics-Based Classification System in Adult Patients with B-Cell Acute Lymphoblastic Leukemia

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

ADGRG1/GPR56 As a Marker of CD8 + Tumor-Reactive T Cells in Acute Myeloid Leukemia

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia

Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only